GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Novoprotein Scientific Co Ltd (SHSE:688137) » Definitions » Capex-to-Operating-Income

Suzhou Novoprotein Scientific Co (SHSE:688137) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Suzhou Novoprotein Scientific Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Suzhou Novoprotein Scientific Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-6.62 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥-7.76 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Suzhou Novoprotein Scientific Co Capex-to-Operating-Income Historical Data

The historical data trend for Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Novoprotein Scientific Co Capex-to-Operating-Income Chart

Suzhou Novoprotein Scientific Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - 0.11 0.36 0.33 -

Suzhou Novoprotein Scientific Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 - - - -

Competitive Comparison of Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income

For the Biotechnology subindustry, Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income falls into.



Suzhou Novoprotein Scientific Co Capex-to-Operating-Income Calculation

Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-44.939) / -5.892
=N/A

Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-6.616) / -7.763
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suzhou Novoprotein Scientific Co  (SHSE:688137) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Suzhou Novoprotein Scientific Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Suzhou Novoprotein Scientific Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Novoprotein Scientific Co (SHSE:688137) Business Description

Traded in Other Exchanges
N/A
Address
No. 228, Yunchuang Road, 3rd & 4th Floor, Wujiang Economic and Technological Development Zone, Jiangsu Province, Suzhou, CHN, 215299
Suzhou Novoprotein Scientific Co Ltd is a high-tech enterprise focusing on recombinant protein application solutions. Its main business is the research and development of target and cytokine proteins, recombinant antibodies, enzymes and reagents, Production and sales, and provide related technical services.

Suzhou Novoprotein Scientific Co (SHSE:688137) Headlines

No Headlines